(NASDAQ: SNGX) Soligenix's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 103.88%.
Soligenix's earnings in 2025 is -$11,457,052.On average, 4 Wall Street analysts forecast SNGX's earnings for 2025 to be -$22,118,883, with the lowest SNGX earnings forecast at -$21,251,476, and the highest SNGX earnings forecast at -$22,769,438. On average, 4 Wall Street analysts forecast SNGX's earnings for 2026 to be -$8,384,600, with the lowest SNGX earnings forecast at -$8,401,746, and the highest SNGX earnings forecast at -$8,260,540.
In 2027, SNGX is forecast to generate -$7,767,329 in earnings, with the lowest earnings forecast at -$8,401,746 and the highest earnings forecast at -$6,989,688.